Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience
Open Access
- 13 June 2019
- journal article
- research article
- Published by Springer Nature in Radiation Oncology
- Vol. 14 (1) , 104
Abstract
Despite recent advances in multimodal treatments, the prognosis of patients with glioblastoma multiforme (GBM) remains poor. The aim of this study was to evaluate the efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with temozolomide (TMZ) for the postoperative treatment of GBM. From February 2012 to February 2018, 80 patients with newly diagnosed and histologically confirmed GBM in our institute were reviewed retrospectively. All patients underwent complete resection or partial resection surgery and then received hypofractionated SIB-IMRT with concomitant TMZ followed by adjuvant TMZ. A total dose of 64 Gy over 27 fractions was delivered to the gross tumor volume (GTV), clinical target volume 1 (CTV1) received 60 Gy over 27 fractions, and CTV2 received 54 Gy over 27 fractions. The progression-free survival (PFS) and overall survival (OS) rates and the toxicities were evaluated. Prognostic factors were analyzed using univariate and multivariate Cox models. The median follow-up was 16 months (range, 5~72 months). The median PFS was 15 months, and the 1-, 2-, and 3-year PFS rates were 56.0, 27.6, and 19.5%, respectively. The median OS was 21 months, and the 1-, 2-, 3-, and 5-year OS rates were 77.6, 41.6, 32.8, and 13.4%, respectively. The toxicities were mild and acceptable. Age, KPS scores and the total number of TMZ cycles were significant factors influencing patient survival. Moderately hypofractionated SIB-IMRT combined with TMZ is a feasible and safe treatment option with mild toxicity and good PFS and OS.Keywords
This publication has 25 references indexed in Scilit:
- Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomideBritish Journal of Radiology, 2013
- Adult glioblastoma multiforme survival in the temozolomide era: A population‐based analysis of Surveillance, Epidemiology, and End Results registriesCancer, 2011
- Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomideJournal of Medical Imaging and Radiation Oncology, 2011
- Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomideRadiotherapy and Oncology, 2010
- Patterns and Timing of Recurrence After Temozolomide-Based Chemoradiation for GlioblastomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Simultaneous Integrated Boost Intensity-Modulated Radiotherapy in Patients With High-Grade GliomasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Patterns of Care and Survival in a Retrospective Analysis of 1059 Patients With Glioblastoma Multiforme Treated Between 2002 and 2007Neurosurgery, 2010
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiformeInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004